ARTICLE / CLIENT ALERT
COVID-19 Legal Developments for Health Services, Emergency Measures in the United Kingdom
March 31, 2020
Read time: 9 min
The UK government has introduced sweeping changes to the UK health legislation as it urgently prepares for the impact of the Coronavirus (COVID-19) pandemic, including increased admissions and demand for intensive care facilities.
In the space of one week, urgent procurements and build programmes have seen the construction of new intensive care unit (ICU) facilities, the conversion of conference space to create a 4,000-bed COVID-19 hospital, and escalated procurement and device approval for ventilators and testing kits.
The changes include an emergency centralisation of national health service (NHS) purchasing decisions (allowing NHS England rather than local clinical commissioning groups to purchase beds and other facilities), simplification of certain health procedures and changes in payments for health services.
Coronavirus Act 2020
The Coronavirus Act 2020 extends to 358 pages of legislation and makes sweeping changes to the various government functions and law relating to pensions, eviction of tenants and the holding of elections.
The Act commenced on 26 March 2020 and expires within two years. Certain provisions do not come into force immediately and will commence pursuant to secondary regulations.
This article considers certain elements of the Act relevant to the provision of health services, namely, changes in respect of the registration of healthcare professionals, negligence indemnification, NHS pensions, management of the deceased and mental health legislation.
Healthcare Professionals
The new bill introduces new registration powers for the Registrars of the Nursing and Midwifery Council (NMC) and the Health and Care Professions Council (HCPC). The aim of these powers is to address staff shortages to manage increases in COVID-19 patients.
The NMC and HCPC will be able temporarily to “register fit, proper and suitably experienced persons as regulated healthcare professionals”. These provisions will enable the re-registration of key healthcare professionals, including doctors, nurses, midwives and paramedic staff, who are retired or who no longer work in the healthcare sector. Measures also include the early registration of final-year students in the same fields in an effort to increase staff numbers.
The UK government also launched a campaign for volunteers to support the COVID-19 response. As of 29 March, 2020, more than 750,000 individuals had volunteered and the scheme has been paused to process the high level of volunteers who have applied.
The Act introduces a new form of unpaid statutory leave and powers to establish a compensation scheme for some loss of earnings and expenses incurred by volunteers.
Indemnification – Protection from Negligence for COVID-19 Services
Under existing NHS legislation, state-backed indemnity schemes provide protection to NHS bodies for negligence claims arising out of the provision of health services. In England, this is known as the Clinical Negligence Scheme for Trusts (CNST). Since 2013, independent providers have been able to join CNST.
The Act includes powers to extend this indemnity coverage for those providing NHS and health and social care activities connected to care, treatment or diagnostic services in respect of the COVID-19 pandemic, or where NHS services are provided by other organisations as a consequence of the pandemic.
These arrangements offer a safety net to all providers of COVID-19 health services, and mean that separate insurance arrangements do not need to be put in place. This will be particularly relevant for independent sector providers of COVID-19 healthcare where those providers are not already members of CNST.
Pensions for Retired Healthcare Professionals
In order to encourage retired healthcare professionals who already receive an NHS pension to return to work, the Act suspends abatement rules on pensionable pay, which would usually apply following a return to employment. This means that healthcare professionals who have recently retired can return to work, and those who have already returned can increase their hours without incurring a negative impact on their pension entitlements.
Managing the Deceased
In anticipation of increased mortality rates, the Act relaxes various legal requirements in respect of the registration of deaths and the management of the deceased. In particular, requirements are reduced in respect of medical practitioner signatures on medical certificates and reports to coroners. Current requirements that informants registering deaths attend personally before a registrar are removed so that death registration may occur remotely.
COVID-19 is a notifiable disease, meaning that any inquest into a death must have a jury. The Act suspends the Coroners and Justice Act 2009 so that there is no duty to hold a jury inquest, although the coroner retains the discretion to hold such an inquest if the coroner considers there is reason to do so.
Mental Health
The Act introduces temporary changes to mental health legislation, including relaxation of requirements relating to the detention and treatment of patients. Temporary amendments also allow for the extension or removal of certain time limits relating to the detention and transfer of patients.
Business Tenancies – Healthcare Facilities and Premises
Where a business tenant (which may include a healthcare provider) occupies premises under a lease, the Act provides that a tenant who cannot pay the rent is protected from forfeiture until at least 30 June 2020. This means that no business tenant can be forced out of its premises if it misses a payment in the next three months. However, the tenant will still be liable for payment of the accrued rent following 30 June 2020. In addition, any enforcement action for non-payment of rent which has already been issued by a property owner is suspended until 30 June 2020.
Coronavirus Emergency Services Provisions by the Independent Sector
On 24 March 2020, NHS England and NHS Improvement announced a national agreement with independent sector healthcare providers to secure all available inpatient capacity resources in every area in England as part of the response to COVID-19.
These national purchasing agreements were enabled by new emergency secondary legislation (The Exercise of Commissioning Functions by the National Health Service Commissioning Board (Coronavirus) Directions 2020) which came into force on 20 March 2020.
These directions move commissioning responsibility from local NHS clinical commissioning groups to NHS England in respect of COVID-19. This means that instead of fragmented local purchasing arrangements in respect of COVID-19 services, a single national agreement and commercial approach has been adopted.
The directions mean that NHS England has responsibility for the commissioning of healthcare services from the independent sector, and for any other function that NHS England deems appropriate for the purposes of directly or indirectly supporting the provision of services by NHS bodies to address COVID-19.
Under the arrangements, a national contract will override any local agreements in place and will operate from 23 March 2020 for a minimum period of 14 weeks.
It is anticipated that independent sector healthcare providers will deliver inpatient respiratory care to COVID-19 patients, urgent time-dependent NHS elective services, diagnostic capacity, and in-patient non-elective care to NHS patients, and will also make clinical and support staff available who are able to be redeployed in other settings. This contracted provision will cover almost 8,000 beds, of which 160 are Intensive Treatment Unit beds and 107 are High Dependency Unit beds.
Under the arrangements, from 23 March to 16 April 2020 independent sector providers may continue to deliver all types of elective care (NHS or private) if there is capacity. However, after 16 April, independent sector providers must only deliver priority urgent elective and urgent cancer pathways (NHS or private). NHS hospitals are under similar requirements.
In practice, this means that there will be minimal (if any) NHS or private provision of non-urgent elective or cancer pathways from 16 April and during the COVID-19 pandemic. This is likely to lead to a backlog of care and may exacerbate some conditions. Consequently, there is likely to be a requirement for significant capacity to deal with these cases when the COVID-19 pandemic has abated.
Reimbursement for Health Services Affected by COVID-19
Many providers of health services will be affected by significant falls in demand for services as a consequence of COVID-19.
In particular, elective care services, dental services, mental health services and certain community services will be significantly adversely affected by rules requiring members of the public to “stay at home,” or where natural patient concerns regarding safety cause patients to delay or defer care and to only seek medical attention in cases of emergency.
For providers of private health services, the UK government’s measures in respect of payments to furloughed employees may provide some assistance.
For independent sector providers of NHS services, negotiations are ongoing in respect of the payment for NHS services which are likely to experience reductions in activity and in order to protect availability of services after COVID-19.
On 20 March 2020, the Cabinet Office issued a Procurement Policy Note – Supplier relief due to COVID-19. This note sets out information and guidance for public bodies on payment of suppliers to ensure service continuity during and after the current COVID-19 outbreak. It requires public bodies, including local government and NHS bodies, to ensure suppliers at risk are in a position to resume normal contract delivery once the outbreak is over.
The note requires public bodies to review their contract portfolio and inform suppliers that they believe are at risk that they will continue to be paid as normal until at least the end of June 2020, and to put in place appropriate payment measures to support supplier cash. If the contract is on a “payment by results” basis, then payment should be on the basis of the previous invoices (for example, the average monthly payment over three months).
Separately, NHS national bodies are issuing regular updates in respect of reimbursement of national health services, including in respect of preparedness and financial arrangements for primary care, dental services and mental health, although at the time of writing, some uncertainty remains regarding reimbursement for providers of national health services who experience reduced activity. There has been recognition of the need to ensure that providers remain viable and continue to trade to deal with likely demands on health services after the outbreak as subsided and financial terms to protect these providers is anticipated although is currently uncertain.

Receivable Financing: COVID-19 Related Issues
ARTICLE / CLIENT ALERT
Receivable Financing: COVID-19 Related Issues
March 31, 2020
Read time: 12 min
The recent worldwide outbreak of COVID-19 has resulted in extraordinary actions, which are currently disrupting economic activity in the United States and globally. As COVID-19 continues to paralyze the economies around the globe, various measures have been taken by the U.S. government to jump-start the economy. However, those measures may be insufficient to stop the recession or the immediate impact on consumer and commercial obligors in finance transactions. Mortgage and asset-backed securities as well as receivables financing transactions are beginning to feel the effects of social distancing and reduced consumer activity. If the efforts to contain the spread of COVID-19 remain ineffectual, the resulting implications for financings secured by such receivables may be severe. Lenders need to consider their options carefully, balancing asset-specific credit risk mitigation with possible liability.
COVID-19 responses, with mandatory closures and “social distancing,” presents particular challenges for consumers and as a result may negatively impact financial sectors that rely on consumer activity. Lenders should focus on asset-specific challenges when evaluating their current credit risks, such as:
- Hospitality and Tourism. The hospitality sector may be impacted far beyond the containment of the virus. As unemployment keeps growing and travel bans are in effect in most countries, this sector, which includes timeshare developers and resort owners, may feel the effects of the market disruption long after the virus is contained to the extent consumers continue to feel uncomfortable traveling. Hospitality industry experts believe it could take 24 months or longer before rates and occupancy levels return.[1] Data from hospitality tracking firm STR showed that compared to 2019 figures, hotel occupancy is down as much as 96% in Italy, 68% in China, 67% in the United Kingdom, 59% in the United States and 48% in Singapore.[2] Around the globe, RevPAR — revenue per available room — is down sharply, in fact much more than the industry experienced after the Sept. 11 terror attacks and after the financial crisis of 2008/2009.[3] Based on current occupancy estimates for the immediate future and historical employment impact rates, 1 million direct jobs, or nearly 3.9 million total jobs, have either been eliminated or will be eliminated in the next few weeks.[4]
- Auto-Loans and Small Business Loans. The auto asset-backed securities (“ABS”) sector is also at risk to be impaired as a result of the market disruption created by the COVID-19 pandemic. Lenders have attempted to alleviate pressures on the underlying borrowers by providing payment extensions. As part of the Coronavirus Aid, Relief and Economic Security Act (“CARES Act”),[5] the federal government allocated $2 trillion in an effort to mitigate the economic fallout from the COVID-19 pandemic,[6] including $367 billion in the form of loans for small businesses impacted by the pandemic[7]; some of those loans could be forgiven. Despite these measures, consumers may still find it challenging to stay current on their loan payments.
- Student Loans. Even before the global pandemic, student loan asset-backed securities had the highest volume of 90-plus day delinquencies among all household debt.[8] With the unemployment rate dramatically increasing, it is certain that more borrowers will default. President Trump and the Department of Education announced it will stop collection proceedings against borrowers who have defaulted on their federal student loans for a minimum period of 60 days, beginning March 13, 2020.[9] However, the plan does not cover private student loans, which amount to over $100 billion. The CARES Act will also provide financial assistance to households below a certain income threshold. The Federal Reserve is supporting lending to households and consumers through the term asset-backed securities loan facility by lending to holders of asset-backed securities collaterized by new loans. These loans include student loans, auto loans, credit card loans and loans guaranteed by the SBA. However, these measures may prove to be insufficient to combat the effects of the market disruption.[10]
- Equipment Finance. On March 20, 2020, Governor Cuomo of the State of New York ordered all non-essential employees to stay home. As of this writing, similar orders have been implemented in 15 states.[11] Such executive orders cause major disruptions in the operations of non-essential businesses. It is very likely that a high percentage of them will not be able to re-open after the virus is contained. Mandatory closures and lack of revenue could cause borrowers to default on their equipment loans and lease payments.
As indicated above, the widespread reach of the COVID-19 pandemic has unfavorably impacted numerous industries and is expected to have a severe and long-lasting impact on receivable financings. In this scenario, most borrowers are expected to draw down on all or most of their available borrowing capacity under their existing credit facilities. Commonly, such financings incorporate the concepts of a borrowing base and a borrowing base deficiency, the occurrence of which not only precludes additional draws by the borrower, but if uncured (and many will be uncured) within what is typically a very short time period, will lead to an event of default. As COVID-19 continues to disrupt the markets, borrowers may be confronted with non-performance from contractual counterparties which will result in borrowers’ inability to meet their own obligations. Despite the actions taken by the U.S. Government, the markets are still facing the prospect of reduced liquidity. There is anxiety that lenders will refuse to fund draw requests due to concerns and unprecedented uncertainty surrounding the global pandemic. In the atmosphere of growing legislative sentiment for loan forbearance and payment freezes on consumer debt, any measures taken by lenders will need to be exercised with prudence to avoid potential liability.
Borrowers and lenders should review their loan documents carefully to determine the appropriate course of action at this time of uncertainty. Lenders may invoke the material adverse change (“MAC”) clause in their credit agreements. Although rare, some definitions of an MAC may provide for carve outs of a certain systemic risk and allocate that risk to a lender or borrower. Most commonly, MAC is defined to cover a material adverse effect (“MAE”) on a borrower’s ability to perform its payment obligations under the credit documents or an MAE on a borrower’s business, operations, financial conditions and assets. The occurrence of an MAC often constitutes an event of default (“EOD”). MAE definitions are heavily negotiated and differ greatly across agreements. The occurrence of an MAE is determined by either an objective test or in the lender’s discretion. In most credit documents, the non-occurrence of an MAC or an EOD are conditions precedent for additional advances. Therefore, an MAC clause violation will allow lenders to decline the requests for additional funding. An MAC clause can be a powerful tool, but one that should be used with caution.
In most jurisdictions, the burden of proof that an MAC has occurred is on the lender. Courts offer no bright-line test to determine whether an MAC/MAE occurred. An MAC clause review is a highly fact-specific[12] and wording-specific inquiry. Both Delaware and New York have decided MAC cases mostly in the context of mergers and acquisitions, but still look to those cases as precedent for the MAC analysis in the financing realm. Both jurisdictions usually require a lender to prove that there has been an event or set of circumstances that has caused “persistent” and “continual” decline to a borrower’s business.[13] For instance, rapid declines in a borrower’s performance year to year (or, in limited cases, shorter terms) could be sufficient evidence that an MAE occurred.[14] As a rule of thumb, the greater the disruption, the stronger a lender’s rationale will be. Additional evidence includes showing of the existence of a substantial threat to the overall earning potential of the business in a durationally significant manner.[15] The overall magnitude of harm to the market caused by COVID-19 remains unknown. This uncertainty may make it hard for lenders to prove that the operational health and financial soundness of a borrower will be affected for any significant period of time.
Since there is no consensus on the interpretation of MAC clauses, lenders contemplating invoking an MAC clause must possess a strong understanding of the facts used to support their decision. Other ways to avoid potential liability are to ensure that the response is proportional, commercially reasonable and in line with market practices. Finally, lenders should be mindful of reputational risks before making any material decisions. In addition to contractual obligations, lenders have a duty of good faith and fair dealing arising under the UCC, and, in certain jurisdictions, pursuant to common law.
Lenders should also consider whether insurance may cover losses arising out of a party’s inability to meet its obligations. Certain specialized insurance products, such as force majeure insurance, trade disruption insurance, political risk insurance or performance bonds may be utilized by lenders and borrowers to seek relief. In the wake of the SARS outbreak in 2002 – 2003, many insurance companies have since excluded viral or bacterial outbreaks from standard interruption policies.[16] Many commercial property insurance policies provide business interruption coverage. However, such policies often require direct physical loss to property of the insured, its customers or its suppliers.[17]
In the aftermath of COVID-19, courts and juries might be especially sympathetic to borrowers. Lenders will be judged in hindsight and there is potential for backlash, particularly because there is a strong regulatory push to allow borrowers to restructure and modify their loans. Since the inquiry into MAC/MAE clauses will be specific to their own facts and depend upon the exact definition of the MAC/MAE clauses, lenders should have a strong understanding of the facts and carefully evaluate their responses to potential credit risks. Lenders might consider evaluating other avenues, before exercising remedies under credit documents. There is a strong possibility lenders will face liability if their premature denial to provide additional funding or declaration of an event of default will cause the borrower to file for bankruptcy, become insolvent or simply go out of businesses. Lenders should consider communicating anticipated changes to borrowers based on the information provided by such borrowers and most recent financial data. In any event, all parties should undertake careful examinations of their loan documents with respect to notice requirements, potential impact on other agreements, insurance coverage and disclosure and clearly communicate their concerns to their counterparties.
Further, given the circumstances caused by the COVID-19 pandemic, lenders will need to carefully evaluate the impact of their exercise of remedies (including refusal to lend) on both their borrowers and their potential recoveries. Without any clear understanding of the magnitude of the problems facing borrowers (from a durational or financial perspective) or the ability of borrowers to recover from a protracted shutdown of the economy, bankruptcy courts will be ill-equipped to facilitate borrower restructurings, and the commencement of bankruptcy by a borrower may well lead to an immediate liquidation. Experience from the financial crisis in 2008 may not be a useful guidepost for lenders, borrowers or the courts as, in that instance the biggest problem was the absence of market liquidity — but at least the borrowers were still operational and functioning. That is not the case today, and the ability of borrowers to restart business and service debt (even if restructured) is not certain.
Authored by Boris Ziser, Stephen M. Schauder, Adam C. Harris and Vera Quagliato.
If you have any questions concerning this Alert, please contact your attorney at Schulte Roth & Zabel or one of the authors.
To assist our clients in navigating the fallout from the current economic dislocation stemming from COVID-19, and in particular, the expected impact on financing transactions, Schulte Roth & Zabel has established the Economic Downturn Response Team.
[1] See “Devastated Hotel Industry Could Take Years to Recover from COVID-19 Pandemic,” Crain’s New York Business, March 16, 2020, here.
[2] Full article “Data Shows Severe Impact of Coronavirus on Global Hospitality Industry,” PhocusWire, March 26, 2020, available here.
[3] Id.
[4] Full article”COVID-19’s Impact on the Hotel Industry,” AHLA, March 25, 2020, available here.
[5] Full text available here.
[6] Full article “Careful or Careless? Perspectives on the CARES Act,” Brookings, March 27, 2020, available here.
[7] Full article “What the Coronavirus Relief Bill Offers for Small Businesses,” CBS News, March 25, 2020, available here.
[8] “From RMBS to SLABS: Is History Repeating Itself?,” The National Law Review, April 3, 2019, available here.
[9] Full article “Education Dept. Will Stop Collections on Student Borrowers in Default,” NPR, March 25, 2020, available here.
[10] Additional measures include: The Federal Reserve has implemented a number of measures to slow down the economic downfall. The Fed will provide liquidity to the primary dealers through a revived program called Primary Dealer Credit Facility. This will aid in keeping the credit markets functioning at a time of stress. The Fed also re-launched the crisis-era Money Market Mutual Fund Liquidity Facility (“MMLF”). Since the virus outbreak, investors have been withdrawing from money market funds and the MMLF should ensure the funds have enough liquidity to accommodate those requests. Additionally, the Fed lowered the rate that it charged banks for loans to 0.25% which is lower than the rate during the Great Recession. This should encourage banks to lend the money to consumers and accommodate withdrawal requests.
[11] Full list is available “State ‘Shelter-in-Place’ and ‘Stay-at-Home’ Orders,” FINRA, March 27, 2020, here and “What is Shelter in Place and Which States Are on Lockdown Due to Coronavirus?,” Newsweek, March 24, 2020, here.
[12] IBP/Tyson Foods cases, See 789 A.2d 14 (Del. Ch. 2001).
[13] See In re IBP, Inc. Shareholders Litigation, 789 A.2d 14 (2001).
[14] See Pan Am Corp. v. Delta Air Lines, Inc., 175 B.R. 438 (S.D.N.Y. 1994); Katz v NVF Co. 100 A.D. 2d 470 (N.Y. App. Div. 1984).
[15] See Akorn v. Fresenius Kabi AG C.A. No. 2018-0300-JTL (Del. Ch. Oct. 1, 2018).
[16] Full article “Why Many Businesses Will Be on the Hook for Coronavirus Losses?,” The Wall Street Journal, Feb. 21, 2020, available here, additional info “Policy Wording Critical as Businesses Assess Coronavirus Claims,” Insurance Business America, Feb. 26, 2020, available here.
[17] Full article “Applying Commercial Property Insurance to COVID-19 Losses,” Law360, March 12, 2020, available here.
This communication is issued by Schulte Roth & Zabel LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. ©2020 Schulte Roth & Zabel LLP.
All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.

Federal Reserve Delays Effective Date of New, More Flexible ‘Control’ Rule for Six Months
ARTICLE / CLIENT ALERT
Federal Reserve Delays Effective Date of New, More Flexible ‘Control’ Rule for Six Months
March 31, 2020
Read time: 3 min
On Jan. 30, 2020, the Federal Reserve Board (“Board”) issued a final rule (to be published in 12 C.F.R. Parts 225 and 238) (“Final Rule”)[1] simplifying and increasing the transparency of its regulations governing determinations of whether a company “controls” another company for purposes of the Bank Holding Company Act (“BHCA”)[2] or the Home Owners’ Loan Act (“HOLA”).[3] At that time, the Final Rule was scheduled to become effective tomorrow, April 1, 2020.
However, the Board announced today that it will delay the effective date for its revised control framework by six months (i.e., from April 1, 2020 to Sept. 30, 2020). The Board indicated that the delay “will reduce operational burden and allow institutions to focus on current economic conditions.” No changes were made to the Final Rule itself.
As discussed in our prior Alert on the Final Rule,[4] we expect it will make investments in bank holding companies, savings and loan holding companies and depository institutions (collectively, “Banking Organizations”) more attractive to investors (including private equity funds, hedge funds and activist investors) and will better facilitate joint ventures and minority investments by Banking Organizations. We also expect the Final Rule to benefit Banking Organizations that sponsor investment funds.
Authored by Joseph P. Vitale and Jessica Romano.
If you have any questions concerning this Alert, please contact your attorney at Schulte Roth & Zabel or one of the authors.
[1] The Final Rule is available here.
[2] 12 U.S.C. §§ 1841, et seq.
[3] 12 U.S.C. §§ 1461, et seq.
[4] “Federal Reserve Provides Greater Clarity and Flexibility for Noncontrolling Investments in (and by) Banking Organizations,” SRZ Alert, Jan. 31, 2020, available here.
This communication is issued by Schulte Roth & Zabel LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. ©2020 Schulte Roth & Zabel LLP.
All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.

Tax and Estate Planning Considerations in Light of COVID-19
ARTICLE / CLIENT ALERT
Tax and Estate Planning Considerations in Light of COVID-19
March 31, 2020
Read time: 5 min
Tax Filing and Payment Deadlines Extended
- In a notice issued on March 20, 2020, the IRS announced that due to the COVID-19 pandemic, all taxpayers (including individuals, trusts and estates) with an income tax payment or filing due on April 15, 2020 will be granted an extension until July 15, 2020 to make such payment or filing. While the IRS had originally placed a limit on the amount of tax that could be postponed, the March 20, 2020 notice removed this limitation.
- In a notice issued on March 27, 2020, the IRS also announced that all taxpayers with federal gift or generation-skipping transfer tax payments or filings due on April 15, 2020 will be granted an extension until July 15, 2020 to make such payments or filings.
- New York has extended the deadline for state income tax payments and filings due on April 15, 2020 to July 15, 2020, according to Governor Cuomo’s Executive Order issued on March 28, 2020.
- Connecticut has extended the deadline for state income tax payments and filings due on April 15, 2020 to July 15, 2020, according to the Department of Revenue Services.
- The New Jersey legislature passed Assembly Bill No. 3841 on March 16, 2020, which would extend the deadline for state income tax payments and filings due on April 15, 2020 to June 30, 2020, but at this time, the bill has not yet been signed into law.
Notarization via Videoconferencing
- By an Executive Order issued on March 19, 2020, Governor Cuomo authorized the notarization of documents by live videoconference through April 18, 2020, provided that specific technical criteria are met. For example, the signer (i) must state that he or she is physically situated in New York, (ii) present valid photo ID during the videoconference (if not personally known to the Notary) and (iii) transmit by fax or electronic means a legible copy of the signed document to the Notary on the same date that it was signed. Please consult your Schulte Roth & Zabel LLP attorney before utilizing remote notarization to ensure that all requirements will be met. See SRZ Alert Remote Notarization in New York State: Temporary Authorization in Response to COVID-19.
Funding Revocable Trusts to Avoid Probate
- New York Surrogate’s Courts are closed for the foreseeable future, which will cause considerable delays in probate. You should consider funding your revocable trust now to ensure your estate is not negatively impacted by the potential delay in probate. Probate assets are frozen and may not be liquidated or used until the will has been probated by the court (or preliminary letters testamentary are granted to the nominated executors).
- Specifically, if your spouse or children (or anyone else) relies on you for support and your estate plan contemplates continuing to provide for them, you should consider funding your revocable trust with, at a minimum, sufficient liquid assets to allow your beneficiaries access to these funds immediately after your death. Further, if you direct the sale of any assets upon your death (or own any assets which should be sold after your death rather than distributed to your beneficiaries), you should fund your revocable trust with these assets so that any potential post-death sales are not impeded due to a delayed probate process.
- If you are unable to fund your revocable trusts, you should find out whether the custodian of your individual accounts permits you to designate your revocable trust as the recipient of that account on death by beneficiary designation.
Remote Availability
- The SRZ Individual Client Services team is working remotely at this time to ensure the health and safety of our staff, clients and community. Our attorneys are committed to providing you with uninterrupted service and remain available by email and telephone. We are currently using Zoom, LoopUp and similar video and telephone conferencing services to conduct meetings.
Please contact your Schulte Roth & Zabel attorney at your earliest convenience if you wish to discuss the above issues as they may apply to your specific financial and personal circumstances, or if you wish to discuss (i) making gifts which take advantage of the increased gift tax exemptions which are scheduled to expire at the end of 2025 (unless Congress acts sooner) or (ii) making loans or selling assets to trusts in order to take advantage of the current low interest rates.
This communication is issued by Schulte Roth & Zabel LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. ©2020 Schulte Roth & Zabel LLP.
All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.

Regulated Funds: SEC Provides Temporary Exemption for Borrowing and Lending Arrangements in Response to COVID-19 Outbreak
ARTICLE / CLIENT ALERT
Regulated Funds: SEC Provides Temporary Exemption for Borrowing and Lending Arrangements in Response to COVID-19 Outbreak
March 31, 2020
Read time: 7 min
On March 23, 2020, in recognition of the current and potential effects of the COVID-19 outbreak, the U.S. Securities and Exchange Commission issued a temporary order (“Order”) providing certain registered investment companies the flexibility to engage in short-term funding arrangements that would otherwise be impermissible under the Investment Company Act of 1940 (“1940 Act”).[1] The Order allows registered open-end management investment companies other than money market funds (“open-end funds”) and insurance company separate accounts registered as unit investment trusts (“separate accounts”) to borrow funds from affiliates and to enter into other lending arrangements, subject to certain conditions. The relief, which is effective for the period from the date of the Order until at least June 30, 2020, is intended to allow funds to manage their portfolios, including potential shareholder redemptions, for the benefit of all shareholders in light of the market disruptions resulting from the COVID-19 situation.
Borrowings from Affiliates
The Order loosens restrictions imposed by the 1940 Act on borrowings by open-end funds and separate accounts if such borrowings are undertaken to satisfy shareholder redemptions. The Order exempts an open-end fund or separate account from the provisions of Section 12(d)(3) of the 1940 Act to the extent necessary to permit such fund to borrow money from affiliates that are not themselves registered investment companies, as well as provides an exemption under Section 17(a) of the 1940 Act to enable an affiliate of an open-end fund or separate account to make collateralized loans to such an open-end fund or separate account, provided that the conditions below are satisfied.[2] Under the Order, an open-end fund is also exempt from the requirements of Section 18(f)(1) to the extent necessary to permit such fund to borrow money from an affiliate that is not a bank or a registered investment company, also subject to the conditions below.[3] The following conditions must be met in order to rely on the relief provided by the Order:
- The board of directors of the open-end fund, including a majority of the directors who are not interested persons of the open-end fund, or the insurance company on behalf of the separate account, reasonably determines that such borrowing:
- Is in the best interests of the registered investment company and its shareholders or unit holders; and
- Will be for the purpose of satisfying shareholder redemptions.
- Prior to relying on the relief for the first time, the open-end fund or separate account notifies the SEC staff via email at IM-EmergencyRelief@sec.gov stating that it is relying on the Order.
Interfund Lending Arrangements
The Order also loosens restrictions on borrowing and lending arrangements involving registered investment companies that are currently able to rely on an SEC order permitting an interfund lending and borrowing facility (“IFL Order”), while also allowing funds without existing IFL Orders to enter into similar borrowing and lending arrangements.
Among other things, the Order allow funds with IFL Orders to increase the amount of the loans made through such interfund facilities, as well as to extend the term of such loans, subject to certain conditions, including that a majority of the independent directors of the fund determines that the term for any interfund loan made in reliance on the Order is appropriate. Loans made under such a facility must otherwise be made in accordance with the terms and conditions of the existing IFL Order. In addition, prior to relying on the relief for the first time, the registered investment company must notify the SEC staff via email at IM-EmergencyRelief@sec.gov stating that it is relying on the Order and must disclose on its public website that it is relying on an SEC exemptive order that modifies the terms of its existing IFL Order to permit additional flexibility to provide or obtain short-term funding from its interfund lending and borrowing facility.
Registered investment companies not currently able to rely on an IFL Order may, pursuant to the Order, establish and participate in an interfund facility as set forth in an exemptive order permitting such a facility that the SEC has issued within the twelve months preceding the date of the Order (“recent IFL precedent”); provided that, with certain exceptions, the registered investment company must satisfy the terms and conditions for relief in the recent IFL precedent (as modified by the relief provided by the Order, as applicable). A fund relying on this relief must also notify the SEC staff via email at IM-EmergencyRelief@sec.gov stating that it is relying on the Order and identifying the recent IFL precedent that it is relying on and must also include certain disclosures on its public website and in any prospectus supplements, new or amended registration statements or shareholder reports that it may file while relying on this relief.
Deviations from Lending or Borrowing Fundamental Policies
The Order also exempts open-end funds from Sections 13(a)(2) and 13(a)(3) of the 1940 Act to the extent necessary to permit such funds to enter into lending or borrowing transactions that deviate from any relevant policy recited in their registration statements without prior shareholder approval, provided that the following conditions are met:
- The board of directors of the open-end fund, including a majority of the directors who are not interested persons of the investment company, reasonably determines that such lending or borrowing is in the best interests of the registered investment company and its shareholders;
- The open-end fund promptly notifies its shareholders of the deviation by filing a prospectus supplement and including a statement on the fund’s public website; and
- Prior to relying on the relief for the first time, the registered investment company notifies the SEC staff via email at IM-EmergencyRelief@sec.gov stating that it is relying on the Order.
Issues to Consider in Relying on the Order
While the relief contained in the Order may provide funds facing significant shareholder redemptions much-needed short-term funding, the boards of directors of such funds, including the directors who are not interested persons of the fund, must consider whether reliance on the Order is appropriate, given the fund’s specific circumstances. Fund boards should work together with a fund’s investment adviser and counsel to the fund and the independent directors to determine whether reliance on this relief is warranted and in the best interest of the fund. Funds should also consider how reliance on the Order reflects on the fund’s liquidity risk management, in light of the public disclosure requirements of the Order.
Authored by Karen Spiegel.
If you have any questions concerning this Alert, please contact your attorney at Schulte Roth & Zabel or one of the authors.
[1] Investment Company Act Release No. 33821 (March 23, 2020), available here.
[2] Section 12(d)(3) of the 1940 Act generally prohibits a registered investment company from acquiring any security (including a note or a loan) issued by a securities-related business, including a broker, dealer, underwriter or investment adviser. Section 17(a) of the 1940 Act generally prohibits purchases and sales of securities or other property between a registered investment company and its affiliates, subject to certain exceptions.
[3] Section 18(f)(1) of the 1940 Act generally prohibits an open-end fund from issuing any senior security, except that an open-end fund can borrow from a bank provided that the fund maintains asset coverage of at least 300% for all of its borrowings.
This communication is issued by Schulte Roth & Zabel LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. ©2020 Schulte Roth & Zabel LLP.
All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.

COVID-19: Health and Welfare Benefits and Relief Included in the CARES Act
ARTICLE / CLIENT ALERT
COVID-19: Health and Welfare Benefits and Relief Included in the CARES Act
March 30, 2020
Read time: 6 min
In the ongoing effort to help individuals impacted by COVID-19, Congress passed the Coronavirus Aid, Relief, and Economic Securities Act (the “CARES Act” or “Act”) on March 27, 2020. The President signed the Act into law the same day. The historic stimulus package provides wide-ranging relief for both employers and employees. This includes rules that impact health and welfare, retirement and executive compensation plans and programs.
For health and welfare plan sponsors, the CARES Act relief includes, among other things, increased access to COVID-19 diagnostic testing and telehealth services, as well as additional reimbursement opportunities for individuals and guidance for plan sponsors. For details about the key retirement plan provisions of the CARES Act, please see our On the Subject here.
A summary of the health and welfare-related provisions of the CARES Act is included below.
FAQs
1. What types of COVID-19 testing must employers provide?
As part of the Families First Coronavirus Response Act, Congress required employer-sponsored group health plans to provide COVID-19 diagnostic testing that has been approved by the Food and Drug Administration (“FDA”) and related services on a first-dollar basis with no cost-sharing for participants (see our recent On The Subject here).
The CARES Act expands the types of COVID-19 diagnostic testing an employer must cover on a first-dollar basis with no cost-sharing to participants to include certain tests that are: (1) subject to or intend to be submitted for an emergency use authorization with the FDA, (2) developed and authorized by a state government, or (3) directed to be covered by the Secretary of Health and Human Services.
2. What rates govern plan sponsor reimbursement to healthcare providers for COVID-19 testing?
For in-network providers, the CARES Act clarifies that if a plan has a negotiated rate with a given provider already in place, that is the amount the plan will pay for COVID-19 testing coverage. If there is no negotiated rate, such as for out-of-network providers, reimbursement is at the “cash price,” unless the plan negotiates a lower rate with the provider. The CARES Act requires providers to post the cash price of tests on their public website and authorizes the Secretary of Health and Human Services to impose a monetary penalty of up to $300 per day on any provider who fails to do so. While unclear, these rules presumably apply to the other items and services that relate to the provision of the diagnostic test or the evaluation of an individual to determine whether a test is necessary—however, more guidance would be appreciated.
3. What types of COVID-19 coverage are employers required to provide?
Group health plans and health insurance issuers offering group or individual health insurance are required to cover, without cost-sharing, any “qualifying coronavirus preventive service.” The CARES Act defines a “qualifying coronavirus preventive service” as an item, service or immunization that is intended to prevent or mitigate COVID-19 and that meets one of the following requirements:
- an evidence-based item or service that has in effect a rating of “A” or “B” in the current recommendations of the United States Preventive Services Task Force, or
- an immunization that has in effect a recommendation from the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention with respect to the individual involved.
4. When must employers begin to cover qualifying coronavirus preventive services?
Coverage for qualifying coronavirus preventive services is required within 15 business days after the date on which a recommendation is made by the applicable government agency relating to such services. This is a quicker timeframe than is currently required under law and would presumably speed up the time in which any COVID-19 vaccine could be made available to individuals.
5. Can employers offer below-market or free telemedicine to provide care during the COVID-19 pandemic for those covered under a high-deductible health plan?
Yes, including care unrelated to COVID-19. For plan years beginning on or before December 31, 2021, the CARES Act permits a high-deductible health plan (“HDHP”) to provide for first-dollar coverage of telehealth and other remote care services without jeopardizing an individual’s eligibility to contribute to a health savings account (“HSA”). As a result, medical care can temporarily be provided through telemedicine for COVID-19 and other conditions without disqualifying an individual from contributing to a health savings account. This expands and solidifies previous IRS guidance allowing first-dollar coverage of telehealth services directly related to testing and treatment of COVID-19 (see our recent On the Subject here).
6. Is it true that the CARES Act permits reimbursement from a health FSA, HRA or HSA of menstrual care products and over-the-counter drugs without a prescription?
Yes. The CARES Act allows reimbursement for over-the-counter (“OTC”) drugs without a prescription from account-based plans, such as health flexible spending accounts (“FSAs”), health reimbursement arrangements (“HRAs”) and health savings accounts (“HSAs”). The CARES Act also permits reimbursement for menstrual care products. Previously, the Affordable Care Act prohibited reimbursement for OTC medicines purchased without a prescription.
7. Are there any special considerations for plan sponsors regarding obligations under the Health Insurance Portability and Accountability Act (“HIPAA”)?
The CARES Act clarifies responsibilities of plan sponsors to safeguard protected health information (“PHI”) of individuals undergoing treatment for substance use disorders. Under the CARES Act, such an individual’s prior written consent must be obtained before PHI is shared with other entities, including HIPAA business associates. An individual undergoing treatment for substance use disorders may provide a single prior written consent for all future disclosures, so long as such consent is not revoked.
The CARES Act also requires the Secretary of Health and Human Services to issue guidance within 180 days following enactment of the CARES Act on sharing PHI during the COVID-19 public health emergency. This guidance will help plan sponsors to comply with HIPAA while dealing with challenging situations related to quarantines, notification of potential exposure to other employees and telework and other employee leave requirements.
Many of the changes required or permitted by the CARES Act will require amendments to plan documents and updates to summary plan descriptions. Plan sponsors should work with third-party administrators, insurers and legal counsel to ensure these changes are implemented correctly and to consider any other legal requirements that might be implicated.
If you have any questions regarding the above, please reach out to your regular McDermott lawyer or one of the listed authors.

Retirement Plan Relief and Temporary Student Loan Benefits in the CARES Act
ARTICLE / CLIENT ALERT
Retirement Plan Relief and Temporary Student Loan Benefits in the CARES Act
March 30, 2020
Read time: 10 min
In its ongoing effort to help individuals affected by the Coronavirus (COVID-19) pandemic, Congress passed the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) on March 27, 2020. The president signed the CARES Act into law the same day. This historic stimulus package provides wide-ranging relief for both employers and employees, and includes rules that affect health and welfare, retirement and executive compensation plans and programs.
For retirement plan sponsors, the CARES Act relief includes relaxed plan distribution and loan rules designed to provide participants with greater access to, and control over, their retirement plan funds, as well as rules that suspend required minimum distributions (RMDs) for 2020. The CARES Act also provides pension plan funding relief for cash-strapped employers, and a long-sought-after, but temporary, opportunity for employers to provide tax-free student loan repayment benefits for the first time. Click here for details about the key health and welfare provisions of the CARES Act.
Read on for a summary of the key retirement-plan-related provisions of the CARES Act.
COVID-19-Related Distributions and Loans
The CARES Act is specifically designed to provide relief to individuals actually affected by COVID-19, including not only those who are diagnosed with COVID-19, but also those who experience adverse financial consequences as a result of, among other things, being quarantined, furloughed or laid off. The CARES Act includes special COVID-19-related in-service withdrawal and distribution rules designed to provide participants with greater access to their retirement plan benefits, and more flexibility to receive those funds without adverse tax consequences. In addition, the new law includes rules designed to provide loan repayment relief for individuals affected by COVID-19.
Does the CARES Act require employers to add COVID-19-related distributions and/or loans to their plans?
No. This relief is optional. Employers may, but are not required to, offer COVID-19-related distributions and loan relief under their plans. However, many employers likely will implement all or part of this relief for their plan participants.
Plan sponsors that want to implement all or part of this relief should contact their recordkeepers for more details regarding the administration of the new rules.
Can employers provide special retirement plan distributions and/or loans to individuals affected by COVID-19?
Yes, but only to “qualified individuals.” A “qualified individual is an individual who meets either of the following requirements:
- A participant who is, or whose spouse or dependent is, diagnosed with SARS-CoV-2 or COVID-19 by a test approved by the Centers for Disease Control and Prevention
- A participant who experiences adverse financial consequences because of being quarantined, furloughed or laid off, or having work hours reduced due to the virus; being unable to work due to lack of childcare on account of the virus; the closing or reduced hours of a business owned or operated by the individual due to the virus; or other factors determined by the Secretary of the Treasury.
Can employers provide special retirement plan distributions to qualified individuals under the CARES Act?
Yes. The CARES Act allows employers to permit qualified individuals (as described previously) to take COVID-19-related distributions, including both in-service withdrawals and post-termination distributions, from their retirement plans, including 401(k) plans, profit sharing plans and 403(b) plans. The new law allows a qualified individual to withdraw up to $100,000 and receive more favorable tax treatment than would otherwise normally apply. The new law also waives the 10% penalty tax on these distributions, assuming the distribution is made prior to December 31, 2020.
The CARES Act also suggests that employers may be able to provide similar tax-favored treatment to certain types of distributions from defined benefit pension plans. However, given the special rules and restrictions that apply to distributions from such plans (including QJSA and in-service distribution restrictions), providing such relief under a defined benefit plan poses unique challenges for employers considering this option.
Are there special rules regarding how COVID-19-related distributions will be taxed under the CARES Act?
Yes. Unless they elect otherwise, participants who receive COVID-19-related distributions will include the distribution in their taxable income ratably over a three-year period (one-third of the distribution each year), beginning with the year the COVID-19-related distribution is received. In other words, a “qualified individual” (as described above) will spread out her tax payments on COVID-19-related distributions over three years. In addition, COVID-19-related distributions are exempt from the 20% mandatory withholding that normally applies to certain retirement plan distributions.
Can COVID-19-related distributions be repaid under the CARES Act?
Yes. COVID-19-related distributions can be repaid by a qualified individual within three years and will not be treated as taxable income if repaid. To date, there is no guidance on how to reverse any income tax previously paid on such amounts, but it is likely that the approach will mirror the rules previously established by the Internal Revenue Service for similar hurricane-related disaster relief.
Does the CARES Act expand access to participant loans?
Yes. The new law doubles the maximum amount a qualified individual may borrow from a tax-qualified retirement plan. A qualified individual may borrow the lesser of $100,000 or 100% of the qualified individual’s vested benefit under the plan (reduced by prior loan balances). This provision greatly expands the amount available for loan. Prior to the new law, the loan limit was the lesser of $50,000 or 50% of the participant’s vested benefit under the plan (reduced by prior loan balances). For example, a participant with a $10,000 vested account balance was previously limited to a $5,000 loan; if this participant is a qualified individual, he can now borrow the full $10,000 from his account. To qualify for the higher loan limits, a retirement plan must make the loan to a qualified individual before September 24, 2020.
Does the CARES Act allow employers to suspend loan repayments for new loans?
Yes. If a qualified individual receives a new loan on or after March 27, 2020, payments due before December 31, 2020 may be delayed for one year.
Does the CARES Act allow employers to suspend loan repayments for existing loans?
Yes. If a “qualified individual” already has an existing plan loan as of March 27, 2020, loan repayments due before December 31, 2020 may be delayed for one year. The loan repayments must resume upon the end of the COVID-19-related suspension period. However, the term of the loan may be extended by the duration of the COVID-19-related suspension period. Interest accruing during the COVID-19-related suspension period must be added to the remaining principal of the loan, which in effect means the loan must be reamortized.
Will employers that offer COVID-19-related distributions and/or loans need to amend their retirement plans to implement these changes?
Yes. If an employer wants to provide the COVID-19-related distributions or plan loans to qualified individuals, the employer will need to amend its plans for these changes by last day of the plan year beginning on or after January 1, 2022 (i.e., for calendar-year plan years, by December 31, 2022).
Suspension of 2020 Required Minimum Distributions
The CARES Act waives all RMDs from defined contribution plans and IRAs otherwise required to be made in 2020. This optional form of relief allows participants to delay RMDs and avoid taking a distribution while the value of their investments is significantly reduced.
Does the CARES Act allow employers to suspend RMD payments from defined contribution plans?
Yes. The new law allows employers to waive any RMD payment that otherwise would have been required to be paid in 2020. Although the language included in the new law is a bit unclear, it appears the intent is for this relief to apply both to participants whose required beginning dates would otherwise be April 1, 2020, and to participants already receiving RMDs and scheduled to continue receiving those payments in 2020.
Does the CARES Act allow employers to suspend required minimum distribution (RMD) payments from defined benefit plans?
No. Employers may suspend RMDs under defined contribution plans but may not suspend similar payments under their defined benefit pension plans.
Does the CARES Act require employers to suspend RMDs due in 2020?
No. As of the publication of this article, this relief appears to be optional. Employers may, but are not required to, suspend RMD payments due in 2020. The new law does not specifically address the options for implementing RMD suspensions for 2020. However, the 2020 RMD suspension rules mirror similar relief provided in 2009. Therefore, plan sponsors should have the same options, i.e., to forego the optional waiver of RMDs and continue paying 2020 RMDs as planned, to waive 2020 RMDs unless a participant elects (opts in) to receive a distribution of such amounts, or to distribute 2020 RMDs unless a participant elects (opts out) a waiver. The options available to employers may depend upon the options supported by their plan’s recordkeeper. Plan sponsors should contact their recordkeepers for more details regarding the administration of the new rules.
Will employers need to amend their retirement plans to implement these changes?
Yes. If an employer wants to suspend RMDs, it will need to amend its plans for these changes by the last day of the plan year beginning on or after January 1, 2022 (i.e., for calendar-year plan years, by December 31, 2022).
Pension Plan Funding Relief
The market volatility caused by COVID-19 is having a significant impact on pension plan funding. To help address the concerns of cash-strapped employers, the CARES Act includes much-needed pension plan funding relief designed to reduce the need for minimum required contributions to such plans for 2020.
Does the CARES Act include pension plan funding relief?
Yes. Under ERISA, pension plan sponsors are required to ensure that their plans are funded at certain set levels. To avoid benefit restrictions, plans generally must be at least 80% funded. To meet this funding requirement, most plan sponsors must make required minimum contributions to their plans each year.
Under the CARES Act, employers may delay minimum funding contributions due during 2020, including quarterly contributions, until January 1, 2021. In addition, for purposes of determining whether a plan is at least 80% funded for purposes of applying benefit restrictions, the plan sponsor may elect to use the plan’s 2019 AFTAP for the 2020 plan year.
Importantly, this relief only delays the minimum funding contributions due in 2020. The amounts will be due on January 1, 2021, and will also be increased for interest.
***
Tax-Free Student Loan Benefits
The CARES Act includes a temporary tax-free student loan repayment benefit. Employers continue to look for new ways to provide tax-advantaged student loan repayment benefits to their employees, as described in our On the Subject. Although the relief is not permanent, it will give employers a way to provide this long-sought-after relief during a period of potentially greater need for employees.
Does the CARES Act include a student loan repayment benefit?
Yes. The new law allows employers to pay up to $5,250 per year for certain educational expenses, which will include student loan payments made by the employer after the law is passed and prior to January 1, 2021. Employers can make these payments to the employees or directly to the lenders. The $5,250 per year is calculated by adding several different education expenses together, including existing tuition assistance programs and student loan repayments. This relief is not permanent—it sunsets at the end of 2020.
Does the student loan repayment benefit affect the student loan interest deduction for employees?
Yes. Any interest paid by an employer may not be deducted by the employee under the student loan interest deduction (i.e., the CARES Act specifically denies a “double benefit” of a tax-free payment from the employer and a tax deduction for the employee).

CMS Expands Accelerated and Advance Payment Program to All Medicare Providers, Suppliers
ARTICLE / CLIENT ALERT
CMS Expands Accelerated and Advance Payment Program to All Medicare Providers, Suppliers
March 30, 2020
Read time: 13 min
Accelerated or advance Medicare payments can provide some cash flow as providers and suppliers combat the effects of the Coronavirus (COVID-19) pandemic. This program requires a one-page application, and funds may be available as soon as seven days after the provider or supplier applies. These payments are subject to automatic recoupment through claims offsets beginning 120 days after payment issuance. In spite of confusion around program eligibility criteria, providers and suppliers should evaluate this opportunity and ensure that their applications are accurate and transparent.
This On the Subject was updated on April 7, 2020.
On March 28, 2020, the Centers for Medicare & Medicaid Services (CMS) issued guidance regarding how providers may access accelerated or advance Medicare payments. CMS has offered this type of relief in the past for providers affected by hurricanes and other natural disasters. CMS announced that the program is now available nationwide during the COVID-19 public health emergency and expanded the scope of providers and suppliers that can take advantage of it.
This CMS action combines steps mandated by Congress in the Coronavirus Aid, Relief, and Economic Security (CARES) Act, which President Donald Trump signed into law on March 27, 2020, with additional program expansions initiated by CMS. The CARES Act directed CMS to expand the Medicare Part A payment acceleration program for hospitals and critical access hospitals (CAHs), while CMS itself took action to expand payment acceleration for Medicare Part B providers and suppliers.
According to the CMS guidance, to be eligible for accelerated or advance payments for Part A or Part B, the hospital, other provider or supplier must:
- Have billed Medicare for claims within 180 days immediately prior to the date of signature on the provider’s/supplier’s request form,
- Not be in bankruptcy,
- Not be under active medical review or program integrity investigation, and
- Not have any outstanding delinquent Medicare overpayments.
As part of a broader regulatory package responding to COVID-19, on March 31, 2020, CMS issued an interim final rule with comment period (comments are due June 1, 2020). The applicability date of the regulations is stated to be March 1, 2020. Among a range of other changes, CMS seeks to modify 42 CFR § 421.214 (the existing advance payment authority for suppliers). Among other technical updates (e.g., changing carrier to contractor), most notably, CMS has provided that:
- Advance payments may be made in “exceptional circumstances,” including when CMS approves the Medicare Administrative Contractors (MACs) making advance payments during the period of Public Health Emergency or Presidential Disaster Declaration under the following “exceptional conditions”:
- The contractor being unable to process the claim timely or is “at risk of being timely in processing the claim”, or
- When the supplier has experienced a temporary delay in preparing and submitting bills to the contractor beyond its normal billing cycle.
- For suppliers qualifying for advance payments pursuant to a Public Health Disaster or Presidential Disaster Declaration, a contractor may disburse an advance payment for a particular claim up to 100% of the anticipated payment for that claim based upon the historical assigned claims payment data. (Existing regulations do not explicitly define “historical assigned claims” but define “historical data” as “a representative 90-day assigned claims payment trend within the most recent 180-day experience before the system malfunction.”)
- Only suppliers that are “in” bankruptcy are ineligible for advanced payments.
The melding of congressionally mandated acceleration for Part A hospitals with CMS’s expansion of pre-existing Part B advance payment programs into a single effort, combined with the admirable speed at which CMS and MACs have been trying to get the acceleration option up and running, has led to inconsistency and confusion about these eligibility criteria and the information that providers and suppliers are required to submit to MACs as part of the payment request. To date, CMS has not clarified beyond what is described above. And there even remains a question about the enforceability of these criteria—at least with respect to Part A hospitals for which the payment acceleration expansion was directed by Congress without these conditions.
In this fast-moving and unclear environment, providers and suppliers should consider applying for accelerated or advance payment regardless of whether they are sure they meet all of the stated eligibility criteria. Applicants should take care, however, that their applications accurately and transparently address any items that reasonably could touch on any of the eligibility criteria stated so far by CMS or the applicable MAC. For specific examples see the discussion below, Eligibility Criteria and Application Contents. Hospitals, other providers and suppliers would be wise, however, to seek advice of counsel on their specific situations, to avoid unanticipated recoupment risk, adverse financial consequences or future enforcement risk based on their acceleration applications.
Program Financial Details
The accelerated payment amount a provider or supplier can request varies. The CARES Act expanded the program for hospitals and CAHs in two notable ways. First, inpatient acute care hospitals, children’s hospitals and certain cancer hospitals are able to request up to 100% of their Medicare payment amount, and CAHs are able to request up to 125% of their Medicare payment amount for a six-month period. Other providers and suppliers not affected by the CARES Act can request these funds for 100% of their Medicare payment amount for a three-month period. Providers and suppliers should keep in mind that they may be asked to submit documentation to support their request, either in connection with the application or at some later date.
Second, while repayment of the advance begins for all participants after 120 days, providers covered by CARES have additional time to repay the balance. Approved participants will receive their prepayment amount and payment for claims submitted. After 120 days, CMS will begin to offset claims for the amount of the accelerated payment. After that, any remaining balance becomes due:
- Inpatient acute care hospitals, children’s hospitals, certain cancer hospitals and CAHs will have up to one year from the date the accelerated payment was made to repay the balance.
- A small subset of Part A providers that receive Period Interim Payment will have their accelerated payment included in the reconciliation and settlement of their final cost report.
- All other Part A providers and Part B suppliers will have 210 days from the date the accelerated or advance payment was made to repay the balance.
CMS’s written guidance does not detail how the MACs are to calculate the payments or the application of interest. CMS’s current position is to have the MACs use data CMS provides on the net reimbursement/claim payments, including pass-through payments, made to the relevant provider/supplier over a three-month or six-month period: October 1 to December 31, 2019, or July 1 to December 31, 2019, respectively.
With respect to the application of interest, CMS confirmed that interest will only apply if a provider or supplier fails to repay the advance or accelerated payment within the 210-day or one-year repayment period, respectively. While the rate is subject to change, based upon the existing regulatory framework it appears that CMS will apply the standard overpayment rate, currently 10.25%. Providers and suppliers should immediately engage with CMS (e.g., through their trade associations and societies) to address the various implementation issues as well as the potentially unintended consequences of the recoupment/offset and application of a significant interest rate at a time when suppliers and providers are, at best, likely to be in the early stages of attempting to recover from the pandemic.
Application Mechanics
To request accelerated or advance payment, a provider or supplier must submit an Accelerated/Advance Payment Request Form specific to the provider or supplier’s MAC. The form is a single page and can be found on the applicable MAC’s website, and must be submitted via mail, fax or email to the MAC. There is still inconsistency between the information requested by the various MACs, but the request form generally includes:
- Provider or supplier’s identification information, including legal business name, correspondence address, National Provider Identifier and any other information required by the MAC
- Amount requested based on the provider or supplier’s need
- Reason for the request (i.e., “Delay in provider/supplier billing process of an isolated temporary nature beyond the provider’s/supplier’s normal billing cycle and not attributable to other third party payers or private patients”) and statement that the request is for an accelerated/advance payment due to the COVID-19 pandemic
- Signature of an authorized representative of the provider or supplier.
The MACs are accepting and processing the Accelerated/Advance Payment Request Form effective immediately, and payment for approved requests is anticipated to be issued within seven calendar days of form receipt. Providers should contact their MAC’s COVID-19 hotline if they have questions about accelerated or advance payment requests.
Eligibility Criteria and Application Contents
As noted, to be eligible for payment acceleration under the CMS-stated criteria, a provider or supplier must have billed Medicare within the last 180 days, must “not be in bankruptcy,” must not be under “active medical review” or “program integrity investigation,” and must “not have any outstanding delinquent Medicare overpayments.” To date, CMS has not elucidated the outer boundaries of “active medical review,” “program integrity investigation” or “outstanding delinquent Medicare overpayment.” MACs generally have not yet expounded upon what these mean.
The application forms that MACs are asking providers and suppliers to submit to receive payment acceleration add further complication by, in some cases, stating additional or different criteria than CMS has done. This variance appears, at least in part, to exist because some MACs have so far simply repurposed pre-existing forms from prior payment acceleration programs whose specifics differed from the new COVID-19 program. For example, while CMS states that an eligible provider cannot “be in bankruptcy,” at least two MACs’ forms ask each provider applicant to certify, under penalty of perjury, that it “has no plans to file for bankruptcy nor has the provider retained bankruptcy counsel” and also that it “has no plans to cease doing business.” Another MAC’s (no doubt repurposed) form adds eligibility criteria of which CMS made no mention in relation to the COVID-19 acceleration program: “The provider does not have any outstanding/accelerated advanced payments pending for more than 90 days,” and “The providers [sic] impaired cash position must be such that it would not be alleviated by receipts anticipated within 30 days of the request.” These form discrepancies may lessen over time as more MACs introduce new forms geared specifically to the current payment acceleration situation directed by the CARES Act and stop repurposing pre-existing forms created for prior, non-identical payment acceleration contexts. But, for providers seeking to apply now, the current crop of forms remains very relevant.
In order to minimize future enforcement risk, providers and suppliers should ensure that their applications and associated certifications are accurate and materially complete with respect to all matters covered in both the MAC-specific application form and the more generalized CMS-set criteria. With respect to CMS criterion #3 above, providers should consider some means of disclosing or otherwise addressing all manner of program review and investigation activities (e.g., Targeted Probe and Educate, Comprehensive Error Rate Testing, Quality Improvement Organization activities, Recovery Audit Contractor activities, any open CMS/SDRP or OIG self-disclosures, any pending qui tam litigation under the False Claims Act, regardless of whether or not the US Department of Justice has intervened), even if the form used currently by the provider’s MAC does not include any reference to pending medical reviews or investigations. Such matters can generally be addressed by inclusion of appropriate disclosures and/or disclaimers in providers’ applications, which experienced healthcare regulatory counsel can help draft.
Similarly, applicants should carefully evaluate any contemplated bankruptcy, other insolvency proceedings or cessation of operations in making their certifications. Care also should be taken to define specifically and transparently what the certifying provider or supplier means by a lack of delinquent overpayments, and any categories of routine overpayments that the certifying provider or supplier is excluding from that definition for purposes of the certification (because, read broadly, CMS eligibility criterion #4 could exclude most providers and suppliers from accessing the program at all).
These steps need not consume much time, effort or other resources to complete, but they will prove very worthwhile to help insulate providers against future enforcement risk after the immediate COVID-19 crisis has passed.
Any provider or supplier whose application for accelerated or advance payments is denied by its MAC should then consult with experienced healthcare regulatory and litigation counsel on its options for recourse. Under CMS guidance, providers and suppliers will not have administrative appeal rights related to these accelerated or advance payments. Administrative appeal rights would apply to the extent CMS issued overpayment determinations to recover any unpaid balances on accelerated or advance payments. However, nothing in the available guidance prohibits providers or suppliers from resubmitting a request if the initial request is denied.
With respect to Part A hospitals and CAHs, specifically, Congress directed the acceleration program expansion through the CARES Act and did not provide for eligibility exclusions except “appropriate safeguards against fraud, waste, and abuse.” Therefore, such entities are likely to have more options to challenge any application denials on administrative law grounds than Part B providers and suppliers may have.
Comparing Accelerated/Advance Payments to the CARES Provider Relief Funding
As physicians and hospitals pursue relief from the COVID-19 pandemic, they should consider other options also available to them and the interplay between these models. The CARES Act created a $100 billion Public Health and Social Services Emergency Fund to prevent, prepare for and respond to the COVID-19 pandemic. The fund is intended to assist physicians, hospitals and other entities that provide diagnosis, testing or care for individuals with possible or actual cases of COVID-19. The CARES Act states that these funds may not be used to reimburse expenses or losses that have been reimbursed from other sources or that other sources are obligated to reimburse.
There are several key distinctions between the Public Health Fund and the Accelerated Payment Program. First, the Public Health Fund is intended to pay providers for costs incurred outside of Medicare or Medicaid reimbursable amounts. Examples include building or construction, medical supplies and equipment, testing supplies, and increased workforce and training. In contrast, the Accelerated Payment Program essentially pre-pays providers for their Medicare services. The Public Health Fund offers new money, whereas the Accelerated Payment Program is essentially a cash advance.
The specific criteria for the Public Health Fund are not yet available, but additional details are expected this week.
Key Takeaways: All Medicare providers and suppliers may now participate in CMS’s Accelerated and Advance Payment Program. These accelerated or advance payments would act as immediate resources to assist providers and suppliers in combatting the spread of COVID-19 in the coming months. To view a sample timeline for these payments, click here. These payments are subject to automatic repayment through claim offsets beginning 120 days after payment issuance. All providers and suppliers should consider applying, regardless of the stated eligibility criteria, but should consult with counsel about how to do so in a compliant manner, in order to avoid creating future enforcement risk.
The McDermott Difference
If your organization is unsure whether a provider entity qualifies for advanced or accelerated payments, or has questions about how to compliantly frame an application and certification, please do not hesitate to contact us for responsive, efficient advice.
This On the Subject was co-authored with Mara McDermott and Dr. Paul Gerrard, Vice Presidents at McDermott+Consulting.


Corporate Authority for Extraordinary Delivery of Care Decisions
ARTICLE
Corporate Authority for Extraordinary Delivery of Care Decisions
March 30, 2020
Read time: 4 min
First in a series of updates on how the pandemic is implicating basic governance topics.
Healthcare providers facing emergency requests from government agencies in response to the Coronavirus (COVID-19) crisis — including critical issues such as transfers of COVID-19 patients, opening closed facilities and increasing bed capacity — should clarify their internal lines of authority (i.e., CEO v. Board) for authorizing extraordinary decisions regarding delivery of care.
Healthcare providers and their board and executive leadership may want to clarify their internal lines of authority for authorizing exceptional Coronavirus (COVID-19) decisions regarding the delivery of care in their facilities.
Many providers are facing, or may soon face, extraordinary emergency requests from governmental agencies relating to critical issues such as accepting transfers of COVID-19 patients, opening closed facilities, increasing bed capacity to address anticipated inpatient flow needs and other fundamental issues regarding the allocation of scarce resources. Responding to these requests casts the board and executive leadership team into uncharted waters in terms of organizational decision making.
From a governance perspective, the key legal question involves determining the appropriate leadership level(s) at which the decision is most appropriately made: (i) solely by the chief executive officer; (ii) by the CEO in consultation with the board chair, a board committee or the board of directors; (iii) by a special committee of the board; (iv) by formal decision of the full board of directors; or (v) though some other means. Presumably, medical and nursing staff leadership will be consulted in whatever process is decided upon. The answer should be the byproduct of board and/or CEO discussion (with general counsel input) reflecting the particular circumstances.
For these unique, COVID-19-related issues, there is no “one size fits all” answer, no “best practice.” Multiple factors may be taken into consideration when clarifying where the decision-making responsibility falls: the materiality of the pending decision, applicable state law, the scope of the provider’s statement of corporate purposes, federal tax exempt status, corporate social responsibility considerations, corporate reputation, etc.
Every organization’s approach is likely to be different and reflective of expectations based on past practice for the allocation of authority between the board and executive leadership.
The ultimate goal is a decision-making protocol for these critical yet novel issues that reflects thoughtful discussion between executive management and the board and demonstrates an informed board exercising its fiduciary responsibilities in a manner it deems appropriate for the circumstances. In other words, ensuring that the question — “Who makes the call?” — is raised, and considered, in a timely manner.
Click here to access the second article in the series, The Executive Committee in Times of Crisis.
Click here to access the third article in the series, Virtual Board Meetings in Times of Crisis.
Click here to access the fourth article in the series, Emergency State Action Affecting Board Processes and Corporate Filings.
Click here to access the fifth article in the series, Assuring Appropriate Information Flow to the Risk and Compliance Committees.
Click here to access the sixth article in the series, Revisiting Executive and Board Succession Planning in Response to the Pandemic.
Click here to access the seventh article in the series, Board Financial Oversight Responsibilities During Pandemic-Driven Distress.
COVID-19 – The Latest German Laws and their Impact on Nursing Care Providers
ARTICLE / CLIENT ALERT
COVID-19 – The Latest German Laws and their Impact on Nursing Care Providers
March 30, 2020
Read time: 2 min
In an expedited proceeding which took place last week, the German Parliament enacted several new laws in response to the ongoing COVID-19 pandemic. Some of them are of particular importance for nursing care providers. The laws will, inter alia, lower the health risk for care home residents and people who need ambulant nursing care, take the pressure off nursing staff by permitting providers to reallocate personnel and allow temporary recruitment of additional trained personnel with eased qualification requirements. Furthermore, nursing care providers will receive additional financial support as quickly as possible.
This article gives an overview of the new laws (in force since March 27 2020) which are of particular relevance for nursing care homes assessing their impact by considering the COVID-19 induced measures and regulations already in force in the nursing care sector.
Read full article in German here.